For example, the PRADA trial evaluated the efficacy of ACE inhibitors and β-blockers in reducing chemotherapy-induced cardiotoxicity, while the CLEOPATRA trial highlighted the cardiac safety of combining targeted therapy with taxanes for HER2-positive BC. The gene discussed is ERBB2; the disease is breast cancer.